Study Collaboration for Successful COVID-19 Vaccine Program

Learn how Veristat supported HIPRA, a European multinational pharmaceutical company, with several international studies to test the efficacy, tolerability, and safety of its RBD dimer recombinant protein vaccine, branded as BIMERVAX®, against SARS-CoV-2. Having specialized in veterinary vaccines over its 50 years, HIPRA relied on Veristat’s extensive human vaccine experience to help the company swiftly progress through its clinical trials. Veristat and HIPRA collaborated to demonstrate the benefits of BIMERVAX^® in adult populations, which included immunocompromised adults as part of the RBDCOV Project. HIPRA engaged Veristat across clinical studies, encompassing the planning and implementation of the pertinent scientific, operational, and biometrics aspects of the clinical trials.  Recently, HIRPA received marketing authorization.   Read the full case study now.   

download